CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with poor outcomes with current therapies. Gemcitabine is the primary adjuvant drug used clinically, but its effectiveness is limited. In this study, our objective was to utilize a rationale-driven approach to identify novel biomarkers...

詳細記述

保存先:
書誌詳細
主要な著者: Colbert, Lauren E., Petrova, Aleksandra V., Fisher, Sarah B., Pantazides, Brooke G., Madden, Matthew Z., Hardy, Claire W., Warren, Matthew D., Pan, Yunfeng, Nagaraju, Ganji P., Liu, Elaine A., Saka, Burcu, Hall, William A., Shelton, Joseph W., Gandhi, Khanjan, Pauly, Rini, Kowalski, Jeanne, Kooby, David A., El-Rayes, Bassel F., Staley, Charles A., Adsay, N. Volkan, Curran, Walter J., Landry, Jerome C., Maithel, Shishir K., Yu, David S.
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4025946/
https://ncbi.nlm.nih.gov/pubmed/24626090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1996
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料